Globes, 6/2/2012 - Teva faces further NIS 200m tax bill
After the Tax Authority issued a tax assessment of NIS 2.7 billion in January, it is due to issue a new assessment for 2005. More Info

Globes, 5/2/2012 - Electra Real Estate sells 2 Norfolk, Virginia, properties
The company will report no profit on the $66 million sale. More Info

Globes, 2/2/2012 - Deutsche Bank, Lazard Freres to seek buyer for Partner
It is not clear whether Ilan Ben Dov's Scailex will remain with any stake in the Orange franchisee. More Info

Globes, 1/2/2012 - "Tshuva has his work cut out to pass the arrangement"
Some Delek Real Estate bondholders object to the proposed debt arrangement, and seek to convene a bondholders meeting. More Info

Globes, 1/2/2012 - El Al CEO: Open skies is irresponsible
Eliezer Shkedi: What is being presented now is liable to cause Israeli aviation to crash. More Info

Globes, 1/2/2012 - Wed: Osem sustains market rise
Osem rose after former CEO Gad Propper sold his stake to Nestle, and HOT rose on news it is distributing a dividend. More Info

Globes, 1/2/2012 - Gad Propper sells Osem stake to Nestle
Nestle has paid NIS 371 million to increase its stake in the Israeli food company to 58.76%. More Info

Globes, 31/1/2012 - Tshuva: I did it my way at Delek Real Estate
Delek Real Estate initialled an agreement with its Series 4 and 5 bondholders, accounting for 75% of the debt. More Info

Globes, 31/1/2012 - Delek Real Estate reaches partial debt settlement
At the last minute, Yitzhak Tshuva's company reached a NIS 1.43 billion deal with the bondholders of two of its three bond series. More Info

Globes, 30/1/2012 - Deadline day looms for Delek Real Estate
Unless there are last minute developments, Yitzhak Tshuva will ask the court on Tuesday for a stay of proceedings. More Info

The Motely Fool, 30/1/2012 - Teva Pharmaceutical's Dividend X-Ray
Looking at a dividend history can tell you more than just a snapshot. More Info

Globes, 29/1/2012 - Teva's Cephalon recalls Treanda leukemia drug
The recall is due to glass fragments that were found in a vial of the drug. More Info

Globes, 29/1/2012 - Teva eyes $2b Indian acquisition - report
"VCCircle" reports that Teva is a contender to acquire Bangalore-based Micro Labs. More Info

Globes, 29/1/2012 - Ben Dov could be set to sell entire Partner stake
Sources: The Orange franchisee's controlling shareholder Scailex will publish the structure of the sale of a bloc of shares. More Info

Globes, 26/1/2012 - Teva raises investment in cell therapy co
Teva is to invest further in MultiGene Vascular Systems, following the completion of its blocked arteries treatment clinical trial. More Info

Globes, 26/1/2012 - Treasury mulls Ashelim auction between 3 finalists
The finalists in the solar power plant tender are Clal Energy, Granite Hacarmel, and France's EDF-Energies Nouvelles. More Info

Jerusalem Post, 25/1/2012 - Delek Real Estate nears bondholders settlement
Bondholders are still deliberating, though, whether to accept or reject the offer. More Info

Globes, 25/1/2012 - Delek Real Estate keeps its options open
Yitzhak Tshuva is waiting till the last moment to decide the company's fate: a debt settlement, or a petition for a stay of proceedings. More Info

TheStreet*, 25/1/2012 - Roche's Illumina Bid May Start War
NEW YORK (TheStreet) -- With news breaking late on Tuesday of Roche's hostile $5.7 billion offer for Illumina, M&A watchers would be wise to remember a similar-sized deal that eventually turned a hostile and resulted in a new buyer and a 20% price increase. In March, 2011, Valeant Pharmaceuticals took a $5.7 billion bid for Cephalon directly to the company shareholders after management called the offer "opportunistic" and talks stalled. The move caused shares to surge above the $73 a share bid price. While the bid eventually failed , optimistic investors were vindicated by a $6.8 billion competing bid from Teva Pharmaceuticals, which valued the company at $81.50 a share. ... Click to view a price quote on ILMN. Click to research the Drugs industry. More Info

Globes, 25/1/2012 - Citi cuts Partner to "Sell"
Citi foresees a grim year ahead for both Partner and Cellcom, and halves its target prices for their shares. More Info

Globes, 24/1/2012 - Hapoalim raises credit margin for contractors
"Bank Leumi has already stopped lending to real estate, and Bank Hapoalim is exploiting the credit crunch to raise prices." More Info

Seeking Alpha, 24/1/2012 - Teva Pharmaceutical Industries Management Presents at 30th Annual J.P. Morgan Healthcare Conference (Transcript)
More Info

Globes, 23/1/2012 - Leo Leiderman sees single-digit home prices correction
Bank Hapoalim's chief economist warns of a credit crunch in Israel this year. More Info

Globes, 22/1/2012 - Sun: Teva rises
Teva rose on news of problems for a Copaxone rival, while Bank Leumi was up after announcing the merger of its mortgage subsidiary. More Info

Globes, 22/1/2012 - Strauss to operate Germany's Viva Coffee plant
Strauss Coffee also has an option to buy the company for €53 million. More Info

Globes, 22/1/2012 - IBI: 11 Gilenya related deaths benefit Teva's Copaxone
IBI: Doctors recommending a treatment for multiple sclerosis will prefer to recommend drugs with a cleaner safety profile, including Copaxone. More Info

Globes, 19/1/2012 - Cellcom sees profit plummeting 60%
In a statement about preparations for a NIS 200-300 million debt issue, the mobile carrier estimates its fourth quarter net profit at NIS 120-130 million. More Info

Globes, 19/1/2012 - Teva, Yanai, and investor illusions
Capital market pressures force CEOs to manage shares instead of managing companies. More Info

Globes, 18/1/2012 - Wed: Teva slips and market dips
Teva was down on the day's biggest turnover, as dual-listed Mellanox and Nice also lost ground. More Info

Globes, 18/1/2012 - Tue: Small gas field discovery fuels market gains
Delek Group and its units Delek Drilling and Avner rose after a small gas prospect was found near the Yam Tethys field. More Info